Atypical phenotype associated with reported GCK exon 10 deletions: Clinical judgement is needed alongside appropriate genetic investigations

Diabetic Medicine

Volumn 30, Issue 8, 2013, Pages

  Thanabalasingham, G ^a,b   Kaur, K ^b,c   Talbot, F ^d   Colclough, K ^e   Mathews, A ^d   Taylor, J ^b,c   Ellard, S ^e,f   Owen, K R ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^e ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLICLAZIDE; GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN; KETONE; METFORMIN; NUCLEOTIDE; ORAL ANTIDIABETIC AGENT; SAXAGLIPTIN; SULFONYLUREA;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG SENSITIVITY; EXON; FALSE POSITIVE RESULT; FEMALE; GENE DELETION; GENE DOSAGE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; POLYDIPSIA; POLYURIA; THERAPY; WEIGHT REDUCTION;

3' UNTRANSLATED REGIONS; ADULT; DIABETES MELLITUS, TYPE 2; DNA MUTATIONAL ANALYSIS; DRUG MONITORING; EXONS; FALSE POSITIVE REACTIONS; FEMALE; GENE DELETION; GLUCOKINASE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MUTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880687428     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12210     Document Type: Article

References (21)

1. Ledermann HM. Maturity-onset diabetes of the young (MODY) at least ten times more common in Europe than previously assumed? Diabetologia 1995; 38: 1482.
2. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010; 53: 2504-2508.
3. Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). Br Med J 2011; 343: d6044.
4. Gill-Carey O, Shields B, Colclough K, Ellard S, Hattersley AT. Finding a glucokinase mutation alters patient's treatment. Diabet Med 2007; 24: 6.
5. Ellard S, Thomas K, Edghill EL, Owens M, Ambye L, Cropper J et al. Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young. Diabetologia 2007; 50: 2313-2317.
6. Garin I, Rica I, Estalella I, Oyarzabal M, Rodriguez-Rigual M. San Pedro JI et al. Haploinsufficiency at GCK gene is not a frequent event in MODY2 patients. Clin Endocrinol (Oxf) 2008; 68: 873-878.
7. Birkebaek NH, Sorensen JS, Vikre-Jorgensen J, Jensen PK, Pedersen O, Hansen T. A de novo whole GCK gene deletion not detected by gene sequencing, in a boy with phenotypic GCK insufficiency. Case Rep Genet 2011; 2011: 768610.
8. Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanne-Chantelot C, Ellard S et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes and hyperinsulinemic hypoglycemia. Hum Mutat 2009; 30: 1512-1526.
9. Ellard S, Bellanne-Chantelot C, Hattersley AT. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008; 51: 546-553.
10. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: e57.
11. Stanik J, Kusekova M, Huckova M, Valentinova L, Masindova I, Stanikova D et al. Impact of Type 2 diabetes on glucokinase diabetes (GCK-MODY) phenotype in a Roma (Gypsy) family - case report. Endocr Regul 2012; 46: 99-105.
12. Calcaterra V, Martinetti M, Salina A, Aloi C, Larizza D. The coexistence of type 1 diabetes, MODY2 and metabolic syndrome in a young girl. Acta Diabetol 2012; 49: 401-404.
13. Schrijver I, Rappahahn K, Pique L, Kharrazi M, Wong LJ. Multiplex ligation-dependent probe amplification identification of whole exon and single nucleotide deletions in the CFTR gene of Hispanic individuals with cystic fibrosis. J Mol Diagn 2008; 10: 368-375.
14. Janssen B, Hartmann C, Scholz V, Jauch A, Zschocke J. MLPA analysis for the detection of deletions, duplications and complex rearrangements in the dystrophin gene: potential and pitfalls. Neurogenetics 2005; 6: 29-35.
15. Ellard S, Bulman MP, Frayling TM, Allen LI, Dronsfield MJ, Tack CJ et al. Allelic drop-out in exon 2 of the hepatocyte nuclear factor-1α gene hinders the identification of mutations in three families with maturity-onset diabetes of the young. Diabetes 1999; 48: 921-923.
16. Raeder H, Bjorkhaug L, Johansson S, Mangseth K, Sagen JV, Hunting A et al. A hepatocyte nuclear factor-4α gene (HNF4A) P2 promoter haplotype linked with late-onset diabetes: studies of HNF4A variants in the Norwegian MODY registry. Diabetes 2006; 55: 1899-1903.
17. Thanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care 2012; 35: 1206-1212.
18. Bonnefond A, Philippe J, Durand E, Dechaume A, Huyvaert M, Montagne L et al. Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene. PLoS One 2012; 7: e37423.
19. Johansson S, Irgens H, Chudasama KK, Molnes J, Aerts J, Roque FS et al. Exome sequencing and genetic testing for MODY. PLoS One 2012; 7: e38050.
20. Steele AM, Tribble ND, Caswell R, Wensley KJ, Hattersley AT, Gloyn AL et al. The previously reported T342P GCK missense variant is not a pathogenic mutation causing MODY. Diabetologia 2011; 54: 2202-2205.
21. Beer NL, Osbak KK, van de Bunt M, Tribble ND, Steele AM, Wensley KJ et al. Insights into the pathogenicity of rare missense GCK variants from the identification and functional characterization of compound heterozygous and double mutations inherited in Cis. Diabetes Care 2012; 35: 1482-1484.